325 related articles for article (PubMed ID: 9767641)
21. Discovery of an orally active non-peptide fibrinogen receptor antagonist based on the hydantoin scaffold.
Stilz HU; Guba W; Jablonka B; Just M; Klingler O; König W; Wehner V; Zoller G
J Med Chem; 2001 Apr; 44(8):1158-76. PubMed ID: 11312916
[TBL] [Abstract][Full Text] [Related]
22. Design and synthesis of novel platelet fibrinogen receptor antagonists with 2H-1,4-benzoxazine-3(4H)-one scaffold. A systematic study.
Anderluh M; Cesar J; Stefanic P; Kikelj D; Janes D; Murn J; Nadrah K; Tominc M; Addicks E; Giannis A; Stegnar M; Dolenc MS
Eur J Med Chem; 2005 Jan; 40(1):25-49. PubMed ID: 15642407
[TBL] [Abstract][Full Text] [Related]
23. Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists.
Malovichko OL; Petrus AS; Krysko AA; Kabanova TA; Andronati SA; Karaseva TL; Kiriyak AV
Bioorg Med Chem Lett; 2006 Oct; 16(20):5294-7. PubMed ID: 16919941
[TBL] [Abstract][Full Text] [Related]
24. Discovery of an orally active series of isoxazoline glycoprotein IIb/IIIa antagonists.
Xue CB; Wityak J; Sielecki TM; Pinto DJ; Batt DG; Cain GA; Sworin M; Rockwell AL; Roderick JJ; Wang S; Orwat MJ; Frietze WE; Bostrom LL; Liu J; Higley CA; Rankin FW; Tobin AE; Emmett G; Lalka GK; Sze JY; Di Meo SV; Mousa SA; Thoolen MJ; Racanelli AL; Olson RE
J Med Chem; 1997 Jun; 40(13):2064-84. PubMed ID: 9207948
[TBL] [Abstract][Full Text] [Related]
25. Antiplatelet efficacy of XV459, a novel nonpeptide platelet GPIIb/IIIa antagonist: comparative platelet binding profiles with c7E3.
Mousa SA; Bozarth JM; Lorelli W; Forsythe MS; Thoolen MJ; Slee AM; Reilly TM; Friedman PA
J Pharmacol Exp Ther; 1998 Sep; 286(3):1277-84. PubMed ID: 9732389
[TBL] [Abstract][Full Text] [Related]
26. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
[TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA
Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406
[TBL] [Abstract][Full Text] [Related]
28. Design of a new class of orally active fibrinogen receptor antagonists.
Klein SI; Molino BF; Czekaj M; Gardner CJ; Chu V; Brown K; Sabatino RD; Bostwick JS; Kasiewski C; Bentley R; Windisch V; Perrone M; Dunwiddie CT; Leadley RJ
J Med Chem; 1998 Jul; 41(14):2492-502. PubMed ID: 9651154
[TBL] [Abstract][Full Text] [Related]
29. Construction of drug screening cell model and application to new compounds inhibiting FITC-fibrinogen binding to CHO cells expressing human alphaIIbbeta3.
Yang J; Yao J; Chen J; Wang XN; Zhu TY; Chen LL; Chu P
Eur J Pharmacol; 2009 Sep; 618(1-3):1-8. PubMed ID: 19619528
[TBL] [Abstract][Full Text] [Related]
30. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
Herault JP; Peyrou V; Savi P; Bernat A; Herbert JM
Thromb Haemost; 1998 Feb; 79(2):383-8. PubMed ID: 9493595
[TBL] [Abstract][Full Text] [Related]
31. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor.
Wang WY; Wu YC; Wu CC
Mol Pharmacol; 2006 Oct; 70(4):1380-9. PubMed ID: 16837624
[TBL] [Abstract][Full Text] [Related]
32. GPIIb/IIIa inhibitors: from bench to bedside and back to bench again.
Armstrong PC; Peter K
Thromb Haemost; 2012 May; 107(5):808-14. PubMed ID: 22370973
[TBL] [Abstract][Full Text] [Related]
33. Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist.
Damiano BP; Mitchell JA; Giardino E; Corcoran T; Haertlein BJ; de Garavilla L; Kauffman JA; Hoekstra WJ; Maryanoff BE; Andrade-Gordon P
Thromb Res; 2001 Oct; 104(2):113-26. PubMed ID: 11672755
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist.
Tsunoda H; Sakuma Y; Harada K; Muramoto K; Katayama S; Horie T; Shimomura N; Clark R; Miyazawa S; Okano K
Arzneimittelforschung; 1990 Nov; 40(11):1201-5. PubMed ID: 2085331
[TBL] [Abstract][Full Text] [Related]
35. Conformational preferences in a benzodiazepine series of potent nonpeptide fibrinogen receptor antagonists.
Keenan RM; Callahan JF; Samanen JM; Bondinell WE; Calvo RR; Chen L; DeBrosse C; Eggleston DS; Haltiwanger RC; Hwang SM; Jakas DR; Ku TW; Miller WH; Newlander KA; Nichols A; Parker MF; Southhall LS; Uzinskas I; Vasko-Moser JA; Venslavsky JW; Wong AS; Huffman WF
J Med Chem; 1999 Feb; 42(4):545-59. PubMed ID: 10052962
[TBL] [Abstract][Full Text] [Related]
36. Blockade of glycoprotein IIb/IIIa by crotavirin, a member of disintegrins, prevents platelet from activation and aggregation by Staphylococcus aureus bacteria.
Liu CZ; Huang HY; Tsai PJ; Shih MH
Thromb Res; 2005; 116(2):145-55. PubMed ID: 15907530
[TBL] [Abstract][Full Text] [Related]
37. Modulation of platelet-neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GPIIb/IIIa receptor.
Xiao Z; Théroux P; Frojmovic M
Thromb Haemost; 1999 Feb; 81(2):281-5. PubMed ID: 10064007
[TBL] [Abstract][Full Text] [Related]
38. Inhibitory effect of a novel orally active GP IIb/IIIa inhibitor, SC-54684A on intimal thickening in the guinea pig femoral artery.
Umemura K; Nishiyama H; Kikuchi S; Kondo K; Nakashima M
Thromb Haemost; 1996 Nov; 76(5):799-806. PubMed ID: 8950793
[TBL] [Abstract][Full Text] [Related]
39. Novel non-peptide GPIIb/IIIa antagonists: synthesis and biological activities of 2-[4-[2-(4-amidinobenzoylamino)-2-(substituted)acetyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl] acetic acids.
Kitamura S; Fukushi H; Miyawaki T; Kawamura M; Terashita Z; Sugihara H; Naka T
Chem Pharm Bull (Tokyo); 2001 Mar; 49(3):258-67. PubMed ID: 11253914
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist.
Moritani Y; Sato K; Shigenaga T; Hisamichi N; Ichihara M; Akamatsu S; Suzuki Ki; Nii T; Kaku S; Kawasaki T; Matsumoto Y; Inagaki O; Tomioka K; Yanagisawa I
Eur J Pharmacol; 2002 Mar; 439(1-3):43-52. PubMed ID: 11937091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
